KD Pharma Group recently appointed Daniel Wiley as vice president of Special Projects, where he will be responsible for leading growth projects in the production of algal omega-3 lipids, cannabinoids and phytochemicals, and other strategic projects.
 
“KD Pharma is successfully executing on a unique growth strategy providing CDMO services for pharmaceutical and nutraceutical customers, while further developing vertical experise in strategic markets,” Oscar Groet, CEO, said. “We are pleased to add Dan’s expertise to the KD Pharma Group – his entrepreneurial mindset and experience in nutritional lipids are valuable assets to help us succeed. Dan complements our company philosophy quite well and we are pleased to add his talents to our dynamic management team.”
 
Daniel Wiley has specialized in nutritional and specialty chemical industry leadership positions, and his skillset lies in both process technology and product marketing. He most recently led the Wiley Ingredients manufacturing division of Wiley Companies, and has nearly two decades of experience in bringing leading nutritional products and services to market successfully.
 
“I am thrilled to be part of the team at the KD Pharma Group. The impressive track record of growth by this organization in inspiring, and I look forward to continuing to execute on developing world-leading capabilities in nutritional lipids and bio-based extracts,” Wiley said.
 
KD Pharma Group is known for manufacturing the Alga3 line of omega-3 concentrates with the highest levels of EPA and DHA available in the market, the company reports. Additionally, it recently formed the KD Phyto business unit to manufacture cannabinoid active pharmaceutical ingredients and plant extracts utilizing its suite of proprietary lipid technologies.